Orginal Article |
|
|
|
|
A Bibliometric Analysis on Coronaviruses |
GONG Yue1,**(),LIAO Qing-yun1,YU Qian-qian1,SHI Zhi-xiang2,**(),CHEN Jing2,ZHANG Yu-hui2,ZHAO Guang-hui2 |
1 National Science Library, Chinese Academy of Sciences, Beijing 100190, China 2 China Pharmaceutical University, Nanjing 211198, China |
|
|
Abstract In late 2019, a novel coronavirus caused febrile respiratory illness(COVID-19) in Wuhan. The continuous spread of COVID-19 in China and its surrounding countries puts forward a new demand for the prevention and control of this epidemic globally. A bibliometric analysis of the research on coronaviruses has been done in this research, and information related to the main countries, core institutions, key research fields were analyzed, which reveals the current research trends of the diagnosis, prevention and treatment of coronaviruses from a global perspective. The results will provide reference for the current joint research.
|
Received: 20 February 2020
Published: 27 March 2020
|
|
Corresponding Authors:
Yue GONG,Zhi-xiang SHI
E-mail: gongy@mail.las.ac.cn;shizhixiangcpu@vip.188.com
|
|
|
[1] |
Huang C, Wang Y, Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020, doi. org/10.1016/S0140-6736(20)30183-5.
doi: org/10.1016/S0140-6736(20)30183-5
|
|
|
[2] |
World Health Organization. Novel coronavirus(2019-nCoV) situation report - 22. [2020-02-17]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2.
|
|
|
[3] |
Ceraolo C, Giorgi F M . Phylogenomic analysis of the 2019-nCoV coronavirus. Journal of Medical Virology, doi.org/10.1002/jmv.25700.
doi: doi.org/10.1002/jmv.25700
|
|
|
[4] |
Wong M C, Javornik Cregeen S J, Ajami N J , et al. Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. bioRxiv, 2020, doi.org/10.1101/2020.02.07.939207.
doi: doi.org/10.1101/2020.02.07.939207
|
|
|
[5] |
Hui D S, I Azhar E, Madani T A , et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis, 2020,91(26):4-6.
|
|
|
[6] |
Zhu N, Zhang D, Wang W , et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 2020, DOI: 10.1056/NEJMoa2001017.
doi: 10.1056/NEJMoa2001017
|
|
|
[7] |
Perlman S . Another decade, Another coronavirus. New England Journal of Medicine, 2020, DOI: 10.1056/NEJMe2001126.
doi: 10.1056/NEJMe2001126
|
|
|
[8] |
Enserink M . Infectious diseases - WHO wants 21st-century reporting regs. Science, 2003,300(5620):717-7188.
|
|
|
[9] |
Brian D A, Baric R S . Coronavirus Genome Structure and Replication. Curr Top Microbiol Immunol, 2005,287:1-30.
|
|
|
[10] |
Woo P C Y, Lau S K P, Lam C S F , et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavir. Journal of Virology, 86(7):3995-4008.
|
|
|
[11] |
中国疾病预防控制中心. 传染性非典型肺炎防治培训教材. 北京: 中国协和医科大学出版社, 2003.
|
|
|
[11] |
Chinese Center for Disease Control and Prevention. Training materials for the prevention and treatment of infectious atypical pneumonia. Beijing: Peking Linion Medical College Press, 2003.
|
|
|
[12] |
Wang G S, Deering C, Macke M , et al. Human coronavirus 229E infects polarized airway epithelia from the apical surface. Journal of Virology, 2000,74(19):9234-9239.
|
|
|
[13] |
Cleri D J, Ricketti A J, Vernaleo J R . Severe acute respiratory syndrome (SARS). Infectious Disease Clinics of North America, 2010,24(1):175.
|
|
|
[14] |
Paules C I, Marston H D, Fauci A S . Coronavirus infections-more than just the common cold. JAMA, 2020, doi: 10.1001/jama.2020.0757.
doi: 10.1001/jama.2020.0757
|
|
|
[15] |
Arabi Y M, Balkhy H H, Hayden F G , et al. Middle East respiratory syndrome. New England Journal of Medicine, 2017,376(6):584-594.
|
|
|
[16] |
Skariyachan S, Challapilli S B, Packirisamy S , et al. Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections. Frontiers in Microbiology, 2019, DOI: 10.3389/fmicb.2019.00569.
doi: 10.3389/fmicb.2019.00569
|
|
|
[17] |
World Health Organization. Emergencies: Novel coronavirus 2019. Geneva:WHO, 2020.
|
|
|
[18] |
World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan,China. Geneva:WHO, 2020.
|
|
|
[19] |
World Health Organization. A research and development blueprint for action to prevent epidemics. Geneva:WHO, 2018.
|
|
|
[20] |
Centers for Disease Control and Prevention. First travel-related case of 2019 novel coronavirus detected in United States CDC press release. Atlanta:CDC, 2020.
|
|
|
[21] |
Bhatnagar P K, Das D, Suresh M R . Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). Journal of Pharmacy and Pharmaceutical Sciences, 2008,11(2):1-13.
|
|
|
[22] |
Jernigan J A, Low D E, Helfand R F . Combining clinical and epidemiologic features for early recognition of SARS. Emerging Infectious Diseases, 2004,10(2):327-333.
|
|
|
[23] |
Chan K H, Poon L, Cheng V C C , et al. Detection of SARS coronavirus in patients with suspected SARS. Emerging Infectious Diseases, 2004,10(2):294-299.
|
|
|
[24] |
Peiris J, Poon L . Detection of SARS coronavirus in humans and animals by conventional and quantitative (real time) reverse transcription polymerase chain reactions. Methods Mol Biol, 2008,454:61-72.
|
|
|
[25] |
Emery S L, Erdman D D, Bowen M D , et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerging Infectious Diseases, 2004,10(2):311-316.
|
|
|
[26] |
Omrani A S, Saad M M, Baig K , et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infectious Diseases, 2014,14(11):1090-1095.
|
|
|
[27] |
Widagdo W, Okba N M A, Stalin Raj V , et al. MERS-coronavirus: From discovery to intervention. One Health, 2017,3:11-16.
|
|
|
[28] |
Clarivate Analytics. DiseaseBriefing:Coronaviruses. [2020-02-17]. https://clarivate.com/wpcontent/uploads/dlm_uploads/2020/01/coronavirus-report-2.14.2020.pdf.
|
|
|
[29] |
Pascal K E, Coleman C M, Mujica A O , et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. PNAS, 112(28):8738-8743.
|
|
|
[30] |
李鹤, 谭晓川, 姜栋 , 等. 冠状病毒及其治疗药物研究进展. 中国药学杂志, 2020.[2020-02-17]. http://kns.cnki.net/kcms/detail/11.2162.r.20200212.2010.004.html.
|
|
|
[30] |
Li H, Tan X C, Jiang D , et al. Coronavirus and its research progress. Chinese Pharmaceutical Journal, 2020.[2020-02-17]. http://kns.cnki.net/kcms/detail/11.2162.r.20200212.2010.004.html.
|
|
|
[31] |
Guan Y . Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science, 302(5643):276-278.
|
|
|
[32] |
周浩, 龙北国, 张文炳 , 等. SARS冠状病毒S2基因原核表达及免疫学特性. 中国公共卫生, 2007(08):962-964.
|
|
|
[32] |
Zhou H, Long B G, Zhang W B , et al. Prokaryotic expression of SARS-CoV S2 gene and preliminary study on its immune characteristics. Chinese Journal of Public Health, 2007(08):962-964.
|
|
|
[33] |
Zhu Z, Chakraborti S, He Y , et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. PNAS, 2007,104(29):12123-12128.
|
|
|
[34] |
Ying T, Du L, Ju T W , et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. Journal of Virology, 2014,88(14):7796-7805.
|
|
|
[35] |
Ohnuma K, Haagmans B L, Hatano R , et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. Journal of Virology, 2013,87(24):13892-13899.
|
|
|
[36] |
Corti D, Zhao J, Pedotti M , et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. PNAS, 112(33):10473-10478.
|
|
|
[37] |
Campanale M, Nucera E, Cesario V , et al. OC.04.1: Nickel free-diet enhances helicobacter pylori eradication rate. Digestive and Liver Disease, 2011,43:S125-S6.
|
|
|
[38] |
Casadevall A, Pirofski L-A, Racaniello V . The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. Plos Pathogens, 11(4):e1004717.
|
|
|
[39] |
Zhou Y, Vedantham P, Lu K , et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research, 2015,116:76-84.
|
|
|
[40] |
Millet J K, Whittaker G R . Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Research, 2015,202:120-134.
|
|
|
[41] |
Kilianski A, Baker S C . Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors. 2014,101(1):105-112.
|
|
|
[42] |
Chu, M C . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 59(3):252-256.
|
|
|
[43] |
Chan J F-W, Yao Y, Yeung M-L , et al. Treatment with lopinavir/ritonavir or interferon-beta 1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. Journal of Infectious Diseases, 2015,212(12):1904-1913.
|
|
|
[44] |
Arabi Y M, Alothman A, Balkhy H H , et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta 1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 2018,19.
|
|
|
[45] |
Cinatl J, Morgenstern B, Bauer G , et al. Treatment of SARS with human interferons. Lancet, 2003,362(9380):293-294.
|
|
|
[46] |
Tan E L C, Ooi E E, Lin C Y , et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases, 2004,10(4):581-586.
|
|
|
[47] |
Stockman L J, Bellamy R, Garner P . SARS: Systematic review of treatment effects. Plos Medicine, 2006,3(9):1525-1531.
|
|
|
[48] |
Robinson W E Jr, Mcdougall B R, Essey R A . Inhibition of HIV reverse transcriptase inhibitor- and protease inhibitor-resistant molecular clones of HIV by the biological response modifier, Ampligen. Antiviral Res, 2000,46(1):A48.
|
|
|
[49] |
Mitchell W, Blick G, Strayer D , et al. A phase IIB prospective, randomized, controlled study evaluating Ampligen during structured treatment interruption (STI) of HAART in HIV infection. Antiviral Res, 2003,57(3):A41.
|
|
|
[50] |
Olsen A L, Morrey J D, Smee D F , et al. Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res, 2007,75(2):104-112.
|
|
|
[51] |
Dong S H, Wang X, Tian S C , et al. Arginine methyltransferase inhibitor 1 exhibits antitumor effects against cervical cancer in vitro and in vivo. Pharmazie, 2018,73(5):269-273.
|
|
|
[52] |
Greffex Inc Publication. Texas A&M University System (TAMUS) and Greffex, Inc. sign agreement to collaborate on advanced process and manufacturing development.[2020-02-19]. https://www.greffex.com/texas-am-university-system-tamus-and-greffex-inc-sign-agreement-to-collaborate-on-advanced-process-and-manufacturing-development/.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|